Dyne Therapeutics Stock Price, News & Analysis (NYSE:DYN) $11.20 +0.12 (+1.08%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$10.36▼$11.3050-Day Range$6.62▼$11.2052-Week Range$6.40▼$15.60Volume473,883 shsAverage Volume682,267 shsMarket Capitalization$687.46 millionP/E RatioN/ADividend YieldN/APrice Target$27.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Dyne Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside142.9% Upside$27.20 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$145,621 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.73) to ($2.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector437th out of 957 stocksPharmaceutical Preparations Industry197th out of 437 stocks 3.6 Analyst's Opinion Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.20, Dyne Therapeutics has a forecasted upside of 142.9% from its current price of $11.20.Amount of Analyst CoverageDyne Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DYN. Previous Next 0.0 Dividend Strength Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYN. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Dyne Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for DYN on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $145,621.00 in company stock.Percentage Held by Insiders32.89% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.73) to ($2.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dyne Therapeutics Stock (NYSE:DYN)Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Read More DYN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DYN Stock News HeadlinesDecember 1, 2023 | americanbankingnews.comStockNews.com Upgrades Dyne Therapeutics (NYSE:DYN) to SellNovember 21, 2023 | finance.yahoo.com3 of the Best Cheap Stocks Under $20 to Buy Now: November EditionDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 7, 2023 | finance.yahoo.comDyne Therapeutics to Present at November Investor ConferencesNovember 3, 2023 | benzinga.comDyne Therapeutics Chief Operating Officer Trades $73K In Company StockOctober 31, 2023 | morningstar.comDyne Therapeutics Inc Ordinary SharesOctober 31, 2023 | finance.yahoo.comDyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical TrialsOctober 31, 2023 | finance.yahoo.comThe Dyne Therapeutics Inc (DYN) Company: A Short SWOT AnalysisDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 30, 2023 | msn.comDyne Therapeutics GAAP EPS of -$0.99 misses by $0.16October 30, 2023 | finance.yahoo.comDyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical MilestonesOctober 24, 2023 | finance.yahoo.comWe Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth CarefullySeptember 28, 2023 | finance.yahoo.comDyne Therapeutics to Present at October Investor ConferencesSeptember 25, 2023 | benzinga.comMyotonic Dystrophy Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)September 22, 2023 | marketwatch.comDyne Therapeutics Gets New FDA Orphan Drug DesignationSeptember 22, 2023 | markets.businessinsider.comDyne Therapeutics's DYNE-101 Gets Orphan Drug Designation From FDASeptember 22, 2023 | msn.comDyne Therapeutics gets FDA orphan drug status for DM1 drugSeptember 20, 2023 | finance.yahoo.comDyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1September 18, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)September 15, 2023 | finance.yahoo.comWhy Shares of Dyne Therapeutics Fell This WeekSeptember 14, 2023 | finance.yahoo.comInsider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics IncSeptember 10, 2023 | msn.comDyne Therapeutics: Muscle Disease Oligo Therapy Developer In Early StagesSeptember 5, 2023 | finance.yahoo.comDyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 24, 2023 | finance.yahoo.comCARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of DirectorsAugust 10, 2023 | msn.comJP Morgan Maintains Dyne Therapeutics (DYN) Overweight RecommendationAugust 3, 2023 | seekingalpha.comDyne Therapeutics GAAP EPS of -$1.08August 3, 2023 | finance.yahoo.comDyne Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsSee More Headlines Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:DYN CUSIPN/A CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees136Year FoundedN/APrice Target and Rating Average Stock Price Target$27.20 High Stock Price Target$34.00 Low Stock Price Target$20.00 Potential Upside/Downside+142.9%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-168,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.57% Return on Assets-79.16% Debt Debt-to-Equity RatioN/A Current Ratio5.67 Quick Ratio5.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book4.52Miscellaneous Outstanding Shares61,380,000Free Float41,189,000Market Cap$687.46 million OptionableOptionable Beta0.78 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Joshua T. Brumm (Age 45)CEO, President & Director Comp: $946.5kMs. Susanna Gatti High M.B.A. (Age 55)Chief Operating Officer Comp: $655.5kDr. Oxana Beskrovnaya Ph.D. (Age 61)Chief Scientific Officer Comp: $631.08kDr. Romesh Subramanian Ph.D. (Age 58)Co-Founder & Advisor Comp: $565.17kMr. Richard William Scalzo M.B.A. (Age 36)Senior VP and Head of Finance & Administration Mr. John Najim M.B.A.Chief Technical OfficerMs. Amy Reilly (Age 49)Senior VP and Head of Corporate Communications & Investor Relations Mr. Daniel Wilson (Age 51)Senior VP & Head of Legal Ms. Kate MitchellVP & Head of Human ResourcesMs. Debra Feldman (Age 52)Chief Regulatory Affairs Officer More ExecutivesKey CompetitorsCentessa PharmaceuticalsNASDAQ:CNTAKura OncologyNASDAQ:KURAArcturus TherapeuticsNASDAQ:ARCTRevance TherapeuticsNASDAQ:RVNCVera TherapeuticsNASDAQ:VERAView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 5,371 shares on 12/1/2023Ownership: 0.189%American Century Companies Inc.Bought 7,389 shares on 11/30/2023Ownership: 0.045%Deutsche Bank AGBought 4,031 shares on 11/24/2023Ownership: 0.035%Walleye Capital LLCBought 280,276 shares on 11/21/2023Ownership: 0.457%Walleye Trading LLCBought 24,326 shares on 11/21/2023Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions DYN Stock Analysis - Frequently Asked Questions Should I buy or sell Dyne Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares. View DYN analyst ratings or view top-rated stocks. What is Dyne Therapeutics' stock price target for 2024? 5 equities research analysts have issued 1 year price objectives for Dyne Therapeutics' shares. Their DYN share price targets range from $20.00 to $34.00. On average, they predict the company's share price to reach $27.20 in the next twelve months. This suggests a possible upside of 142.9% from the stock's current price. View analysts price targets for DYN or view top-rated stocks among Wall Street analysts. How have DYN shares performed in 2023? Dyne Therapeutics' stock was trading at $11.59 on January 1st, 2023. Since then, DYN stock has decreased by 3.4% and is now trading at $11.20. View the best growth stocks for 2023 here. When is Dyne Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our DYN earnings forecast. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NYSE:DYN) announced its quarterly earnings results on Monday, October, 30th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.16. What ETFs hold Dyne Therapeutics' stock? ETFs with the largest weight of Dyne Therapeutics (NYSE:DYN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Dyne Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dyne Therapeutics investors own include iShares Preferred and Income Securities ETF (PFF), Micron Technology (MU), IVERIC bio (OPHT), SentinelOne (S), Starbucks (SBUX), SunPower (SPWR), Apollo Investment (AINV), Argos Therapeutics (ARGSQ), Broadcom (AVGO) and Bausch Health Companies (BHC). When did Dyne Therapeutics IPO? (DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (2.97%), Armistice Capital LLC (1.96%), Vivo Capital LLC (1.69%), FMR LLC (1.38%), Assenagon Asset Management S.A. (1.18%) and Northern Trust Corp (0.64%). Insiders that own company stock include Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Richard William Scalzo, Susanna Gatti High and Wildon Farwell. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:DYN) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.